XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Cash collections from financial royalty assets $ 1,181,354 $ 1,094,094
Cash collections from intangible royalty assets 71,377 75,200
Other royalty cash collections 32,716 14,088
Distributions from equity method investees 27,502 22,003
Interest received 3,262 2,332
Derivative collateral received 0 11,470
Derivative collateral posted 0 (9,340)
Development-stage funding payments - ongoing (1,106) (5,763)
Development-stage funding payments - upfront and milestone (100,000) 0
Payments for operating and professional costs (93,003) (81,764)
Interest paid (86,880) (64,500)
Net cash provided by operating activities 1,035,222 1,057,820
Cash flows from investing activities:    
Distributions from equity method investees 0 523
Investments in equity method investees (3,050) (17,427)
Purchases of equity securities (62,785) 0
Proceeds from equity securities 0 109,367
Purchases of available for sale debt securities (79,158) (35,170)
Proceeds from available for sale debt securities 31,250 31,250
Purchases of marketable securities (234,869) (728,025)
Proceeds from sales and maturities of marketable securities 525,907 868,689
Acquisitions of financial royalty assets (175,093) (683,741)
Acquisitions of other financial assets (21,215) 0
Milestone payments 0 (18,600)
Net cash used in investing activities (19,013) (473,134)
Cash flows from financing activities:    
Distributions to non-controlling interests (215,543) (238,197)
Distributions to non-controlling interests- other (72,343) (86,978)
Dividends to shareholders (165,312) (138,564)
Contributions from non-controlling interests- R&D 731 4,080
Contributions from non-controlling interests- other 3,247 8,574
Net cash used in financing activities (449,220) (451,085)
Net change in cash and cash equivalents 566,989 133,601
Cash and cash equivalents, beginning of period 1,541,048 1,008,680
Cash and cash equivalents, end of period $ 2,108,037 $ 1,142,281